secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001171843-25-001689
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q4 net loss $12.1M, cash $52M; atopic dermatitis Phase 1 shows 37% EASI 75 vs 0% placebo
--------------------------------------------------------------------------------

- Net loss for Q4 2024 was $12.1M vs $6.7M in Q4 2023; full-year R&D expense $19.4M.
- Cash, equivalents and securities $52.0M as of Dec 31, 2024, up from $27.1M, with runway into Q1 2026.
- Atopic dermatitis Phase 1 cohorts 1-2: 26% of soquelitinib patients achieved IGA 0/1, 37% EASI 75 vs 0% placebo.
- Phase 3 registrational trial of soquelitinib in PTCL is enrolling; Phase 2 ALPS trial initiated under NIAID.
- Approximately $18.6M cash from early exercise of 5.3M warrants; 11.8M warrants remain outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325001689/0001171843-25-001689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325001689/f8k_032525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer